AUSTIN, TX – 01 June 2021 – CDISC is teaming up with Microsoft to develop the CDISC Open Rules Engine (CORE), open-source software that executes machine-readable CDISC Conformance Rules. The global clinical research community will be able to leverage the CORE software to test study data for conformance to CDISC standards as well as regulatory and sponsor-specific conformance rule sets.
Keep up to date with the latest developments at CDISC and follow our news feeds!
DANBURY, CT and AUSTIN, TX – 22 Apr 2021 – CDISC and the National Organization for Rare Disorders (NORD®) have announced a partnership to develop global data standards for rare diseases. The data standards will be released in a Therapeutic Area User Guide that will be available at no cost on the CDISC website for researchers to leverage in studies to maximize data’s full potential.
BRUSSELS, BELGIUM and AUSTIN, TX – 20 April 2021 – The Global Information for Public Health Transformation (GIPHT) initiative of the Learning Health Community has collaborated with CDISC to develop a minimum set of key data elements for documenting vaccinations. The goal of the collaboration is to achieve multinational agreement around one global core data standard that will enable the success of vaccine credentialing applications and secure sharing of essential information for uses such as safe travel.
Austin, TX and Copenhagen, DK – 31 Mar 2021 – CDISC announced a collaboration with A3 Informatics to create industry-standard Biomedical Concepts with the goal of supporting their awareness and encouraging their adoption in clinical research. CDISC Biomedical Concepts form a reference information model that standardizes clinical research concepts and their representation in underlying data models.
Austin, TX – 17 December 2020 – CDISC announced that industry veteran David A. Evans will join the organization as its new President and Chief Executive Officer effective January 1, 2021. Dave brings over 35 years’ experience serving in various executive-level positions in software development, clinical research, regulatory and healthcare industries. He is recognized industry-wide as a leading technology visionary for developing and implementing complex process and system solutions and as an expert in the areas of information standards, regulatory compliance and quality governance. The architect and developer of the first electronic drug submission to the US FDA in 1985, Dave has been responsible for more than 100 electronic regulatory submissions and complex